Monday, May 28, 2018
 
 
Company News: Page (1) of 1 - 10/13/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Sleep Disorders Therapeutics Development and Professional Review Analysis 2017

(October 13, 2017)
Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Summary

This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

 

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.



 

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

 

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

 

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

 

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

 

Scope

- Which companies are the most active within the pipeline for sleep disorder therapeutics?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

 

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

 

Table of Content: Key Points

 

1 Table of Contents 4

    1.1 List of Tables 5

    1.2 List of Figures 6

2 Introduction 7

    2.1 Sleep Disorders Report Coverage 7

    2.2 Restless Legs Syndrome - Overview 7

    2.3 Nocturia - Overview 7

    2.4 Insomnia - Overview 7

3 Therapeutics Development 8

    3.1 Restless Legs Syndrome 8

    3.2 Nocturia 11

    3.3 Insomnia 14

4 Therapeutics Assessment 21

    4.1 Restless Legs Syndrome 21

    4.2 Nocturia 27

    4.3 Insomnia 33

5 Companies Involved in Therapeutics Development 39

    5.1 Restless Legs Syndrome 39

    5.2 Nocturia 42

    5.3 Insomnia 44

6 Dormant Projects 53

    6.1 Restless Legs Syndrome 53

    6.2 Nocturia 53

    6.3 Insomnia 54

7 Discontinued Products 56

    7.1 Restless Legs Syndrome 56

    7.2 Insomnia 56

8 Product Development Milestones 58

    8.1 Restless Legs Syndrome 58

    8.2 Nocturia 63

…Continued        

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts    

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: [email protected]
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com



Source: www.abnewswire.com


Page: 1


Related Keywords:Business,Health & Medicine,Pharmaceuticals & Biotech,Science,World,
Related Sites: DMN Newswire ,   DMN Newswire ,   HTN - Health Technology Net ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Tutorial Finder ,   Review Seeker ,   Review Seeker ,   DMN Newswire Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Global Chromatography Reagents Market Analysis, Growth, Trends & Forecast 2018-2023, With The Market Forecasted to Register a CAGR of More Than 7% - ResearchAndMarkets.com
  • Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023

    Cancer
  • Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Bavarian Nordic Announces Interim Results for the First Three Months of 2018
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines